- Conference Call and Webcast Today, February 6, 2023 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Feb. 6, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022 .

PASADENA, Calif. --(BUSINESS WIRE)--Feb. 2, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of

PASADENA, Calif. --(BUSINESS WIRE)--Jan. 25, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022 .

Fibrosis regression observed in 50% of patients receiving fazirsiran Median reductions of 94% of Z-AAT accumulation in the liver and mean reduction of 68% in histologic globule burden Treatment emergent adverse events were generally well balanced between fazirsiran and placebo groups Results

PASADENA, Calif. --(BUSINESS WIRE)--Dec. 21, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present on January 9, 2023 , at 11:15 a.m. ET at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco .

- Announcement on January 9, 2023 , with Webcast at 8:30 a.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Dec. 21, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023 , at 8:30 a.m. ET , it will present topline data from the SEQUOIA Phase 2 study evaluating

PASADENA, Calif. --(BUSINESS WIRE)--Dec. 20, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of olpasiran.

PASADENA, Calif. --(BUSINESS WIRE)--Dec. 15, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 9, 2022 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to

- Arrowhead Earns $15 million Milestone from Horizon Therapeutics plc PASADENA, Calif. --(BUSINESS WIRE)--Dec. 8, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million

- Conference Call and Webcast Today, November 28, 2022 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Nov. 28, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022 . The company is hosting a conference call today,